Menekse Öztürk
YOU?
Author Swipe
View article: CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes Open
In this case series, we report the first off-label use of the CD19xCD3 T cell engager blinatumomab in two patients with generalized myasthenia gravis (MG). Refractory MG remains a major therapeutic challenge, with patients experiencing sev…
View article: Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis Open
Introduction: The efficacy of anti-CD20 antibodies has significantly contributed to advancing our understanding of disease pathogenesis and improved treatment outcomes in relapsing-remitting multiple sclerosis (RRMS). A comprehensive analy…
View article: C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis Open
Background Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing dis…
View article: Increased Disability Progression in <scp>rs10191329<sup>AA</sup></scp> Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations
Increased Disability Progression in <span>rs10191329<sup>AA</sup></span> Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations Open
Objective We examined the impact of the rs10191329 genetic risk variant on neuroaxonal damage as measured by serum neurofilament light chain (sNfL) levels, and disability progression in people with multiple sclerosis (pwMS). Methods In a c…
View article: Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort Open
View article: Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study Open
Introduction Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the most common immune neuropathies leading to severe impairments in daily life. Current treatment options include intravenous immunoglobulins (IVIG), which ar…
View article: Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Open
View article: Eculizumab versus rituximab in generalised myasthenia gravis
Eculizumab versus rituximab in generalised myasthenia gravis Open
Objective Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizu…
View article: Does a Red House Affect Rhythms in Mice with a Corrupted Circadian System?
Does a Red House Affect Rhythms in Mice with a Corrupted Circadian System? Open
The circadian rhythms of body functions in mammals are controlled by the circadian system. The suprachiasmatic nucleus (SCN) in the hypothalamus orchestrates subordinate oscillators. Time information is conveyed from the retina to the SCN …